Loading
A phase 2 trial of Berubicin in glioma & glioblastoma, run by CNS Pharmaceuticals, Inc., active and no longer recruiting.
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme is a phase 2 interventional study registered as NCT04762069 by CNS Pharmaceuticals, Inc., with 252 participants enrolled, started 2021-05-18 and due to reach its primary completion in 2026-04-27. Interventions recorded: Berubicin and Lomustine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/